For patients without the aforementioned comorbidities with the primary goal of glycemic and weight management, GLP-1 and GIP/GLP-1 receptor agonists are recommended.(1) GLP-1 receptor agonists are not only efficacious for glucose lowering and achieving diabetes treatment goals, but have also demonstrated several added benefits in recent studies
Patients who receive potassium supplements or patients with impaired renal function who are also receiving spironolactone therapy are particularly at risk for developing hyperkalemia
How is Rybelsus able to be given orally
10 In large adult randomized controlled trials, tirzepatide demonstrated substantial weight-loss efficacy, with mean body weight reductions of up to 20.9% over 72 weeks, surpassing outcomes observed with semaglutide monotherapy
Wegovy (semaglutide 2.4 mg) is a prescription-only glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for weight management in adults with obesity or overweight with weight-related comorbidities
We uncover the truth about Melanotan II Nasal tanners are trending, but are they safe
